[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024005304A - Derivado del acido fenilpropionico sustituido y uso del mismo. - Google Patents

Derivado del acido fenilpropionico sustituido y uso del mismo.

Info

Publication number
MX2024005304A
MX2024005304A MX2024005304A MX2024005304A MX2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A
Authority
MX
Mexico
Prior art keywords
acid derivative
phenylpropionic acid
substituted phenylpropionic
disclosure provides
substituted
Prior art date
Application number
MX2024005304A
Other languages
English (en)
Inventor
Jian Li
Zhen Zhang
Min Liu
Yunfei Li
Liang Tan
Xiaoyan Lin
Jiao Li
Yuqiong Dong
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2024005304A publication Critical patent/MX2024005304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona un derivado de ácido fenilpropiónico sustituido y un uso del mismo. Específicamente, la invención proporciona un compuesto como se muestra en la Formula II o una sal medicinal del mismo, que puede usarse en la preparación de un fármaco para prevenir y/o tratar enfermedades cardiovasculares. (ver Fórmula).
MX2024005304A 2021-11-03 2022-11-03 Derivado del acido fenilpropionico sustituido y uso del mismo. MX2024005304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111293711 2021-11-03
CN202211033065 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (1)

Publication Number Publication Date
MX2024005304A true MX2024005304A (es) 2024-05-17

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005304A MX2024005304A (es) 2021-11-03 2022-11-03 Derivado del acido fenilpropionico sustituido y uso del mismo.

Country Status (9)

Country Link
EP (1) EP4428129A1 (es)
JP (1) JP2024540183A (es)
KR (1) KR20240091010A (es)
CN (1) CN118055927A (es)
AU (1) AU2022381258A1 (es)
CA (1) CA3235992A1 (es)
MX (1) MX2024005304A (es)
TW (1) TW202334116A (es)
WO (1) WO2023078333A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326822A2 (en) * 2000-10-11 2003-07-16 Esperion Therapeutics Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
EP1452521A4 (en) * 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
WO2005068410A1 (en) * 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
BR0318685A (pt) * 2003-12-24 2006-12-19 Esperion Therapeutics Inc compostos de cetona e composições para controle de colesterol e usos relacionados
MA56115A (fr) 2019-06-07 2022-04-13 Lilly Co Eli Composés de pyrrolidine

Also Published As

Publication number Publication date
CA3235992A1 (en) 2023-05-11
WO2023078333A8 (zh) 2023-08-10
CN118055927A (zh) 2024-05-17
TW202334116A (zh) 2023-09-01
WO2023078333A1 (zh) 2023-05-11
JP2024540183A (ja) 2024-10-31
KR20240091010A (ko) 2024-06-21
EP4428129A1 (en) 2024-09-11
AU2022381258A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
PH12016502355B1 (en) Pharmaceutical composition
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EP4342473A3 (en) Compounds useful in hiv therapy
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
EP4364741A3 (en) Polymorphic form of tg02
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
MX2023013194A (es) Compuesto inhibidor de atr que contiene sulfoximina.
MX2024004327A (es) Moleculas pequeñas para el tratamiento del cancer.
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.